포유류 다클론 IgG 항체 시장 보고서 : 유형, 제품, 용도, 최종 용도, 지역별(2025-2033년)

The global mammalian polyclonal IgG antibody market size reached USD 1,141.8 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 1,702.6 Million by 2033, exhibiting a growth rate (CAGR) of 4.31% during 2025-2033. The market growth is driven by the increasing collaborations between research institutes and industry players, the rising focus on monoclonal and polyclonal antibody research, the expanding global healthcare infrastructure, the growing use in autoimmune disease treatment, the escalating adoption of recombinant antibodies, and significant growth of the contract research organization (CRO) industry.

Mammalian polyclonal immunoglobulins (IgG) antibody refers to antigens or vaccinations that are manufactured through inoculation of various mammals, including mice, rabbits, and goats. During this procedure, an antigen is administered via injectable into the mammal body to activate the B-lymphocytes that supply IgG. These antibodies are used in labeling reagents in multiple immunoassay tests, including enzyme-linked immunosorbent assay (ELISA), western blot tests, immunoradiometric assay (IRMA), and radioimmunoassay (RIA). Apart from this, the process does not require skilled professionals to produce large batches of vaccinations. Mammalian polyclonal IgG antibody helps create multiple therapeutics, diagnose various ailments, and perform antibody identification and flow cytometry. As a result, they find extensive applications in biochemical research to detect denatured proteins and examine diseases and their treatments. At present, they are commercially available in cardiac, metabolic, and renal marker product variants.

Mammalian Polyclonal IgG Antibody Market Trends:

Increasing prevalence of chronic diseases

The increasing number of cases of chronic diseases, such as cancer, cardiovascular disease, and autoimmune diseases, is a major factor leading to the expansion of the mammalian polyclonal IgG antibody market size. For instance, the prevalence of individuals aged 25 and older with at least one chronic disease, based on 28 recorded diagnoses in general practice, rose from 34.9% in 2004 to 41.8% in 2011, reflecting a statistically significant increase of 6.9 percentage points during that period. As these conditions require more sophisticated diagnostics and management, mammalian polyclonal IgG antibodies are commonly used in immunoassays, directed therapy, and modulation of the immune system. Due to the persistent growth in chronic medical conditions, the prevalent need for relative antibody-based and other solutions contributes to the further advancement of the market.

Rising demand for therapeutic antibodies

The rising demand for therapeutic antibodies is a key factor augmenting the mammalian polyclonal IgG antibody market share. Therapeutic antibodies are increasingly used in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases, due to their high specificity and ability to target disease-causing agents effectively. As biopharmaceutical companies develop more antibody-based therapies, the demand for polyclonal IgG antibodies, which are essential in immune response modulation and research applications, is growing. Additionally, advancements in antibody engineering and an increased focus on personalized medicine further enhance the adoption of therapeutic antibodies. This rising demand fuels research, development, and production of mammalian polyclonal IgG antibodies, contributing to significant market growth and expanding their applications in modern healthcare.

Significant growth in the biotechnology and pharmaceutical industries

The growth of the biotechnology and pharmaceutical industries is a significant driver of the market. As these industries expand, there has been increasing investments in research and development (R&D) activities involving innovative therapeutic and diagnostic solutions. Polyclonal IgG antibodies play a critical role in drug discovery, disease diagnostics, and therapeutic development, especially for complex diseases like cancer and autoimmune disorders. Continual advancements in biopharmaceutical technologies, such as antibody engineering, and the push for biologics and biosimilars are also driving the demand for these antibodies, leading to increased production and wider applications for these antibodies. Additionally, the industry's focus on personalized medicine and precision therapies increases the need for high-quality antibodies, further providing a boost to the market.

Key Market Segmentation:

Breakup by Type:

• Goat
• Rabbit
• Horse
• Mouse
• Others

Breakup by Product:

• Cardiac Markers
• Metabolic Markers
• Renal Markers
• Others

Breakup by Application:

• ELISA
• Immunoturbidimetry
• Immunoelectrophoresis
• Antibody Identification
• Immunohistochemistry
• Immunocytochemistry
• Western Blotting

Breakup by End Use:

• Hospitals
• Diagnostic Centers
• Academic and Research Institutes

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global mammalian polyclonal IgG antibody market. Detailed profiles of all major companies have also been provided. Some of the companies covered include:

• Abbiotec Inc.
• Abcam plc
• Bio-Rad Laboratories Inc.
• Cell Signaling Technology Inc.
• Creative Diagnostics
• Elabscience Biotechnology Inc.
• Geno Technology Inc.
• Merck KGaA
• Proteintech Group Inc.
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

• 1.How big is the global mammalian polyclonal IgG antibody market?
• 2.What is the expected growth rate of the global mammalian polyclonal IgG antibody market during 2025-2033?
• 3.What are the key factors driving the global mammalian polyclonal IgG antibody market?
• 4.What has been the impact of COVID-19 on the global mammalian polyclonal IgG antibody market?
• 5.What is the breakup of the global mammalian polyclonal IgG antibody market based on the type?
• 6.What is the breakup of the global mammalian polyclonal IgG antibody market based on the product?
• 7.What is the breakup of the global mammalian polyclonal IgG antibody market based on the application?
• 8.What is the breakup of the global mammalian polyclonal IgG antibody market based on the end use?
• 9.What are the key regions in the global mammalian polyclonal IgG antibody market?
• 10.Who are the key players/companies in the global mammalian polyclonal IgG antibody market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Mammalian Polyclonal IgG Antibody Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Type

• 6.1 Goat
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Rabbit
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Horse
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Mouse
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Product

• 7.1 Cardiac Markers
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Metabolic Markers
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Renal Markers
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 ELISA
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Immunoturbidimetry
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Immunoelectrophoresis
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Antibody Identification
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast
• 8.5 Immunohistochemistry
  • 8.5.1 Market Trends
  • 8.5.2 Market Forecast
• 8.6 Immunocytochemistry
  • 8.6.1 Market Trends
  • 8.6.2 Market Forecast
• 8.7 Western Blotting
  • 8.7.1 Market Trends
  • 8.7.2 Market Forecast

9 Market Breakup by End Use

• 9.1 Hospitals
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Diagnostic Centers
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Academic and Research Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 Abbiotec Inc.
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
  • 15.3.2 Abcam plc
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
    • 15.3.2.3 Financials
    • 15.3.2.4 SWOT Analysis
  • 15.3.3 Bio-Rad Laboratories Inc.
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
    • 15.3.3.3 Financials
    • 15.3.3.4 SWOT Analysis
  • 15.3.4 Cell Signaling Technology Inc.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
  • 15.3.5 Creative Diagnostics
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Elabscience Biotechnology Inc.
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 Geno Technology Inc.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Merck KGaA
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Proteintech Group Inc.
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
  • 15.3.10 STEMCELL Technologies Inc.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 Thermo Fisher Scientific Inc.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
    • 15.3.11.3 Financials
    • 15.3.11.4 SWOT Analysis